TG Therapeutics Inc [TGTX] stock prices are down -0.50% to $17.87 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TGTX shares have gain 33.76% over the last week, with a monthly amount glided 5.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, March 2024, TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum. In a post published today on Yahoo Finance, TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below.
From an analyst’s perspective:
TG Therapeutics Inc [NASDAQ: TGTX] stock has seen the most recent analyst activity on August 02, 2023, when Goldman upgraded its rating to a Neutral and also revised its price target to $12 from $16. On May 20, 2022, BofA Securities initiated with a Underperform rating and assigned a price target of $5 on the stock. B. Riley Securities reiterated its Buy rating and decreased its price target to $35 on February 23, 2022. Goldman downgraded its rating to a Sell and reduced its price target to $26 on November 15, 2021. Goldman started tracking with a Neutral rating for this stock on April 20, 2021, and assigned it a price target of $50. In a note dated April 19, 2021, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $79 to $89.
The stock price of TG Therapeutics Inc [TGTX] has been fluctuating between $6.46 and $35.67 over the past year. Currently, Wall Street analysts expect the stock to reach $18.4 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $17.87 at the most recent close of the market. An investor can expect a potential return of 2.97% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
The TG Therapeutics Inc [NASDAQ:TGTX] reported sales of 233.66M for trailing twelve months, representing a surge of 54863.75%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is -0.01 and Total Capital is 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.43 points at the first support level, and at 16.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.28, and for the 2nd resistance point, it is at 18.70.
TG Therapeutics Inc [TGTX] reported earnings per share of -$0.1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.1/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.73 per share as compared to estimates of $0.12 per share, a difference of $0.61 representing a surprise of 508.30%.
Ratios To Look Out For
It’s worth pointing out that TG Therapeutics Inc [NASDAQ:TGTX]’s Current Ratio is 5.92. On the other hand, the Quick Ratio is 5.18. Considering the valuation of this stock, the price to sales ratio is 11.81, the price to book ratio is 16.86 and price to earnings (TTM) ratio is 1267.38.
Transactions by insiders
Recent insider trading involved Charney Laurence N, Director, that happened on Jan 05 when 17500.0 shares were sold. CFO, Power Sean A completed a deal on Jan 03 to sell 47867.0 shares. Meanwhile, CEO and President WEISS MICHAEL S bought 100000.0 shares on Aug 11.
